May 09, 2014 (ACCESSWIRE via COMTEX) Whitefish, MT / May 9, 2014 / Biotechnology stocks have had a rough quarter, with the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) falling more than 6% since February. Investors have started to re-evaluate the sector s lofty valuations, while higher interest rates in the near future could slow the M&A frenzy. As a result, investors may want to shift their attention to high-growth bargains in the industry. Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing innovative immune system manipulation therapies, is on the cusp of beginning wide scale animal and human clinical trials that could catalyze the stock upwards after three years of quietly developing its technology. With the recent correction in biotechnology stocks, investors may want to take a closer look. Also see: Premier Biomedical, Inc. and the Wild West of Modern Medicine Clinical Trials Premier Biomedical recently announced that they have initiate
http://bit.ly/1uK5oXx
No comments:
Post a Comment